ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation

T. Horwedel,1 L. Bowman,1 W. Chapman,2 J. Hagopian.1

1Barnes-Jewish Hospital, St. Louis, MO
2Washington University in St. Louis, St. Louis, MO.

Meeting: 2015 American Transplant Congress

Abstract number: A209

Keywords: Immunosuppression, Liver transplantation, Renal function

Session Information

Session Name: Poster Session A: Liver: Immunosuppression and Rejection

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to reduce tacrolimus (TAC) exposure was recently shown to provide superior renal function 36 months post-OLT compared with patients on standard TAC therapy.

Methods: We performed a retrospective cohort study of adult OLT recipients transplanted since 2013 who were placed on a CNI-minimization regimen (TAC trough goal 3-5 ng/mL) with EVR (goal trough 3-8 ng/mL). Clinical pharmacists prospectively identified patients based on eGFR (30-70 mL/min), absence of proteinuria (urine protein <500mg/day), total cholesterol <350 mg/dL, and fasting triglycerides <500 ng/dL. The primary endpoint was the change in renal function from CNI-minimization, as assessed by eGFR at 4, 12, and 24 weeks post-conversion. Renal function was compared with a cohort of patients meeting the same criteria, who remained on standard TAC therapy (goal trough 6-10 mg/mL).

Results: In total, 42 patients met criteria and were converted to EVR, and were compared to 42 control patients. There were no differences in race, sex, CMV risk, hepatocellular carcinoma or primary diagnoses between groups, however 4 patients in the control arm had a rejection. MELD, cold ischemic time, and creatinine at transplant were well-matched. Median time to conversion was 108 days, and this was used as reference time in the control arm. Baseline mean eGFR was similar across arms (58.6 vs. 57.3 mL/min, p = 0.665) There was a significantly higher mean change in eGFR in week 4, week 12 and week 24 in the EVR conversion arm (-1.5 mL/min in the control arm vs +6.4 mL/min in the EVR arm, p = 0.029). No treatment-limiting adverse events occurred in either group through 24 weeks of follow-up.

Conclusion: We note a significant improvement in renal function for patients on EVR compared to those on standard TAC, demonstrating successful implementation of a pharmacist-driven CNI-minimization strategy following OLT.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Horwedel T, Bowman L, Chapman W, Hagopian J. Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/pharmacist-led-renal-sparing-conversion-to-everolimus-after-liver-transplantation/. Accessed May 31, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences